Natalizumab discontinuation in a Dutch real-world cohort

被引：3

作者：

Coerver, E. M. E. ^{[1
]}

Wessels, M. H. J. ^{[1
]}

van Lierop, Z. Y. G. ^{[1
]}

van Kempen, Z. L. E. ^{[1
]}

Killestein, J. ^{[1
]}

Strijbis, E. M. M. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, MS Ctr Amsterdam, Amsterdam Neurosci, Dept Neurol,Amsterdam Univ Med Ctr, Amsterdam, Netherlands

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2021年 / 52卷

关键词：

Multiple sclerosis; Natalizumab; Treatment discontinuation; MS;

D O I：

10.1016/j.msard.2021.102974

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.

引用

页数：3

共 50 条

[21] Dabigatran discontinuation in "real-world" practice among Chinese population
Ho, M. H.
Cheung, E.
Ho, C. W.
Tse, H. F.
Siu, C. W.
EUROPEAN HEART JOURNAL, 2014, 35 : 1104 - 1104
[22] Switching from natalizumab to alemtuzumab in patients with RRMS: real-world experience
Fortin, J.
Jacques, F. H.
Fokko, V. Sikati
Grand'Maison, F.
Emond, F.
Bakdache, F.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 783 - 783
[23] Safety and effectiveness of natalizumab in a real-world multiple sclerosis Portuguese population
Sequeira, M.
Ferro, M.
Barros, A.
Sousa, A.
Sequeira, J.
Parra, J.
Brum, M.
Pedrosa, R.
Capela, C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 868 - 869
[24] Lessons learned after 20 years of real-world experience with natalizumab
Khatri, Bhupendra O.
Olapo, Tayo
Beals, Sara
Lindman, Emily
Perea, Toni
Van Zealand, Pamela
Metzger, Ryan R.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 80
[25] Real world effectiveness of Natalizumab extended interval dosing in a French cohort
Pelle, J.
Briant, A.
Lebrun-Frenay, C.
Cohen, M.
Mondot, L.
De Seze, J.
Bigaut, K.
Collongues, N.
Kremer, L.
Ricard, D.
Bompaire, F.
Sallansonnet-Froment, M.
Ohlmann, C.
Ciron, J.
Biotti, D.
Pignolet, B.
Parienti, J.
Defer, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 207 - 207
[26] The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care
Jeroen W. G. Derksen
Geraldine R. Vink
Marloes A. G. Elferink
Jeanine M. L. Roodhart
Helena M. Verkooijen
Wilhelmina M. U. van Grevenstein
Peter D. Siersema
Anne M. May
Miriam Koopman
Scientific Reports, 11
[27] The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care
Derksen, Jeroen W. G.
Vink, Geraldine R.
Elferink, Marloes A. G.
Roodhart, Jeanine M. L.
Verkooijen, Helena M.
van Grevenstein, Wilhelmina M. U.
Siersema, Peter D.
May, Anne M.
Koopman, Miriam
SCIENTIFIC REPORTS, 2021, 11 (01)
[28] Adherence and persistence to ocrelizumab in a real-world cohort
Rodriguez Regal, Ana
Lopez Real, Ana Maria
Alvarez Rodriguez, Elena
Garcia-Estevez, Daniel Apolinar
Rodriguez Rodriguez, Maria
Pato, Antonio
Costa, Eva
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1014 - 1014
[29] EFFECTIVENESS OF ALECTINIB IN A REAL-WORLD US COHORT
Ramagopalan, S.
Sammon, C.
Rathore, L. S.
Arora, S.
Ray, J.
VALUE IN HEALTH, 2020, 23 : S422 - S422
[30] Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients
Verkkoniemi-Ahola, Auli
Hartikainen, Paivi
Hassi, Katja
Kuusisto, Hanna
Lahdenpera, Sanni
Mehtala, Juha
Viitala, Matias
Ylisaukko-oja, Tero
Soilu-Hanninen, Merja
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2023, 9 (04)

← 1 2 3 4 5 →